We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




FDA Agrees to Review Amalgam Dental Filling Dangers

By HospiMedica staff writers
Posted on 16 Jun 2008
The U.S. More...
Food and Dug Administration (FDA, Rockville, MD, USA) has agreed to complete a regulatory review on the dangers of Mercury amalgam dental fillings by July 2009, as part of the settlement of a lawsuit--filed in December 2007 in U.S. District Court in Washington (DC, USA)--by a collection of environmental groups, consumers, and U.S. state officials. The FDA is awaiting more short-term data exposure from certain patient groups before it makes a final decision on the regulatory review, which began in 2002. The process could result in a requirement that prescribing information of dental amalgam warn dentists and pregnant women of nervous system dangers to fetuses and young children with neurological brain development.

"Gone are all of FDA's claims that no science exists that amalgam is unsafe,” said Michael Bender of Vermont (USA), a plaintiff in the lawsuit. "The FDA has moved to a more neutral course, while still recognizing the serious health risks posed by amalgam in particular for children and unborn children, for pregnant women, and for those with mercury immuno-sensitivity.”

As part of the same settlement, the FDA has also updated some of the safety concerns regarding amalgam stating, "Dental amalgams contain mercury, which may have neurotoxic effects on the nervous systems of developing children and fetuses. When amalgam fillings are placed in teeth or removed from teeth, they release mercury vapor. Mercury vapor is also released during chewing. FDA's rulemaking will examine evidence concerning whether release of mercury vapor can cause health problems, including neurological disorders, in children and fetuses.”

The dental amalgam controversy, which has been raging for decades, centers around the long-term health effects of toxicity or allergy which may be associated with constant mercury exposure, particularly as a potential cause of chronic illnesses, autoimmune disorders, neurodegenerative diseases, birth defects, and mental disorders. Scientists agree that mercury amalgam fillings expose the bearers to a daily dose of mercury, but different studies have concluded that this exposure may be as low as 1-3 µg/day, or as high as 27µg/day. The American Dental Association (ADA, Chicago, Il, USA) reviewed 34 studies and found no evidence that the fillings release mercury vapor when chewing. In addition, they say that the fillings pose no more risk than the mercury found in fish and other food.


Related Links:
U.S. Food and Dug Administration
American Dental Association

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Dual Chamber Warming Cabinet
D-Series
New
Critical Care Cart
Avalo
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.